{
  "variants": [
    {
      "gene": "LRRK2",
      "protein_change": {
        "reference": "Y",
        "alternate": "C",
        "position": "1699"
      },
      "variant_string_id": "LRRK2 Y1699C",
      "acmg_flowchart": {
        "step_1": {
          "judgment": "Yes",
          "reason": "The paper explicitly links LRRK2 mutations to Parkinson's disease (PD) and focuses on GTPase activity and dimerization in the catalytic core as the disease mechanism."
        },
        "step_2": {
          "judgment": "Yes",
          "reason": "The assays (GTPase activity and dimerization) directly evaluate the functional impact of variants, which aligns with the disease mechanism."
        },
        "step_3": {
          "step_3a": {
            "judgment": "No",
            "reason": "The abstract does not explicitly mention wild-type controls or replicates, though comparisons to R1441C and T1348N are implied."
          },
          "step_3b": {
            "judgment": "Yes",
            "reason": "The study uses R1441C and T1348N (known pathogenic variants) as controls, meeting the criteria for variant controls."
          },
          "evidence_strength": "PS3_supporting"
        },
        "step_4": {
          "step_4a": {
            "judgment": "No",
            "reason": "The abstract does not mention statistical analyses, p-values, or OddsPath calculations."
          },
          "step_4b": {
            "judgment": "No",
            "reason": "The number of variant controls (R1441C, T1348N) is less than 11, so the evidence strength remains PS3_supporting."
          }
        }
      }
    },
    {
      "gene": "LRRK2",
      "protein_change": {
        "reference": "R",
        "alternate": "C",
        "position": "1441"
      },
      "variant_string_id": "LRRK2 R1441C",
      "acmg_flowchart": {
        "step_1": {
          "judgment": "Yes",
          "reason": "The paper explicitly links LRRK2 mutations to PD and focuses on GTPase activity and dimerization in the catalytic core as the disease mechanism."
        },
        "step_2": {
          "judgment": "Yes",
          "reason": "The assays (GTPase activity and dimerization) directly evaluate the functional impact of variants, which aligns with the disease mechanism."
        },
        "step_3": {
          "step_3a": {
            "judgment": "No",
            "reason": "The abstract does not explicitly mention wild-type controls or replicates, though comparisons to Y1699C and T1348N are implied."
          },
          "step_3b": {
            "judgment": "Yes",
            "reason": "The study uses Y1699C and T1348N (known pathogenic variants) as controls, meeting the criteria for variant controls."
          },
          "evidence_strength": "PS3_supporting"
        },
        "step_4": {
          "step_4a": {
            "judgment": "No",
            "reason": "The abstract does not mention statistical analyses, p-values, or OddsPath calculations."
          },
          "step_4b": {
            "judgment": "No",
            "reason": "The number of variant controls (Y1699C, T1348N) is less than 11, so the evidence strength remains PS3_supporting."
          }
        }
      }
    },
    {
      "gene": "LRRK2",
      "protein_change": {
        "reference": "T",
        "alternate": "N",
        "position": "1348"
      },
      "variant_string_id": "LRRK2 T1348N",
      "acmg_flowchart": {
        "step_1": {
          "judgment": "Yes",
          "reason": "The paper explicitly links LRRK2 mutations to PD and focuses on GTPase activity and dimerization in the catalytic core as the disease mechanism."
        },
        "step_2": {
          "judgment": "Yes",
          "reason": "The assays (GTPase activity and dimerization) directly evaluate the functional impact of variants, which aligns with the disease mechanism."
        },
        "step_3": {
          "step_3a": {
            "judgment": "No",
            "reason": "The abstract does not explicitly mention wild-type controls or replicates, though comparisons to Y1699C and R1441C are implied."
          },
          "step_3b": {
            "judgment": "Yes",
            "reason": "The study uses Y1699C and R1441C (known pathogenic variants) as controls, meeting the criteria for variant controls."
          },
          "evidence_strength": "PS3_supporting"
        },
        "step_4": {
          "step_4a": {
            "judgment": "No",
            "reason": "The abstract does not mention statistical analyses, p-values, or OddsPath calculations."
          },
          "step_4b": {
            "judgment": "No",
            "reason": "The number of variant controls (Y1699C, R1441C) is less than 11, so the evidence strength remains PS3_supporting."
          }
        }
      }
    }
  ]
}